Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $920.59, giving the company a market capitalization of 95.24B. It carries a P/E multiple of 20.38 and pays a dividend yield of 0.40%.
On 2026-11-21, Regeneron(REGN) stock moved within a range of $916.66 to $948.42. With shares now at $920.59, the stock is trading +0.4% above its intraday low and -2.9% below the session's peak.
Trading activity shows a volume of 856.83K, compared to an average daily volume of 892.58K.
The stock's 52-week range extends from a low of $591.52 to a high of $991.73.
The stock's 52-week range extends from a low of $591.52 to a high of $991.73.
REGN News
...
On Wednesday, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) Livsayis (cemdisiran) for generalized myasthenia gra...
Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Regeneron. The associated price target remains the same with $1,050.00. Evan Seigerma...
Analyst ratings
67%
of 30 ratingsMore REGN News
Alnylam (ALNY) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved Livsayis, an Alnylam-discovered RNAi therapeutic that was...
Regeneron Pharmaceuticals (REGN) has received U.S. approval for Livsayis (cemdisiran), an RNA therapeutic developed with Alnylam Pharmaceuticals (ALNY) as a tre...
Regeneron (REGN) announced new and updated data from its hematology portfolio and pipeline will be shared across 14 abstracts at the American Society of Hematol...
Regeneron Pharmaceuticals received past FDA approval for Livsayis (cemdisiran) to treat anti acetylcholine receptor antibody positive generalized myasthenia gra...
CytomX Therapeutics (CTMX) announced it will receive a $5 million payment after reaching a preclinical milestone in its cancer drug development partnership with...
CytomX Therapeutics (CTMX) announced the achievement of a preclinical milestone for one of the lead programs in its collaboration with Regeneron (REGN), trigger...
Regeneron wins EU nod for alternative Libtayo regimen Nov 17, 2026, 2:17 PM ET Regeneron Pharmaceuticals, Inc. (REGN) Stock By : Dulan Lokuwithana, SA News Edit...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.